All In Biotech

Free tool

FAERS Monitor: Lexette

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210566 or its brand name (Lexette, Halobetasol Propionate). Reports on generic versions are filed under their own applications.

Reports

918

Serious

259

28% of reports

Hospitalization

101

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective198
  • psoriasis135
  • pruritus91
  • product use in unapproved indication73
  • rash65
  • dry skin50
  • arthralgia49
  • dermatitis atopic49
  • skin exfoliation45
  • pain44
  • product dose omission issue38
  • therapeutic product effect incomplete38
  • fatigue35
  • off label use34
  • injection site pain33

Reports by year received

View as table
YearReports
20053
20062
20103
20116
20129
201314
201411
201526
201636
201727
201831
201946
202063
202172
2022140
2023233
202474
202567
202655

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,241 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal13523.720.32,928
dermatitis atopicSignal4921.316.2930
therapeutic product effect incompleteSignal3812.29.0382
skin exfoliationSignal4512.29.2454
dry skinSignal508.66.6329
product use in unapproved indicationSignal736.85.4356
pruritusSignal915.44.5330
drug ineffectiveSignal1983.43.0363
rashSignal653.42.7111
product dose omission issueSignal383.02.248
arthralgiaSignal492.72.152
injection site painSignal332.51.828
pain441.61.211
fatigue351.00.70
off label use340.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.